Key result
Thioridazine was not associated with an overall increased risk of cardiac arrest or ventricular arrhythmia compared with haloperidol, except at doses >=/day.
Why the study?
Does oral thioridazine or other antipsychotic therapy increase the risk of cardiac arrest and ventricular arrhythmia compared with haloperidol or non-schizophrenic controls in outpatients with schizophrenia?
Cohort (n=124,718)
Yes
Does oral thioridazine or other antipsychotic therapy increase the risk of cardiac arrest and ventricular arrhythmia compared with haloperidol or non-schizophrenic controls in outpatients with schizophrenia?
Patients with treated schizophrenia have elevated rates of cardiac arrest and ventricular arrhythmia compared with non-schizophrenic controls, and while overall risk with thioridazine is no worse than haloperidol, high-dose thioridazine (>=600 mg/day) carries a higher arrhythmic risk, warranting use of the lowest effective dose.
Answers are grounded in this paper and cite their sources.
High-dose thioridazine may increase arrhythmic risk; leaves open comparative safety versus haloperidol at standard doses in schizophrenia.
Objective: To examine the rates of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia and in non-schizophrenic controls. Design: Cohort study of outpatients using administrative data. Setting: 3 US Medicaid programmes. Participants: Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis. Main outcome measure: Diagnosis of cardiac arrest or ventricular arrhythmia. Results: Patients with treated schizophrenia had higher rates of cardiac arrest and ventricular arrhythmia than controls, with rate ratios ranging from 1.7 to 3.2. Overall, thioridazine was not associated with an increased risk compared with haloperidol (rate ratio 0.9, 95% confidence interval 0.7 to 1.2). However, thioridazine showed an increased risk of events at doses 600 mg (2.6, 1.0 to 6.6; P=0.049) and a linear dose-response relation (P=0.038). Conclusions: The increased risk of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia could be due to the disease or its treatment. Overall, the risk with thioridazine was no worse than that with haloperidol. Thioridazine may, however, have a higher risk at high doses, although this finding could be due to chance. To reduce cardiac risk, thioridazine should be prescribed at the lowest dose needed to obtain an optimal therapeutic effect. What is already known on this topic Thioridazine seems to prolong the electrocardiographic QT interval more than haloperidol Although QT prolongation is used as a marker of arrhythmogenicity, it is unknown whether thioridazine is any worse than haloperidol with regard to cardiac safety What this study adds Patients taking antipsychotic drugs had higher risks of cardiac events than control patients with glaucoma or psoriasis Overall, the risk of cardiac arrest and ventricular arrhythmia was not higher with thioridazine than haloperidol Thioridazine may carry a greater risk than haloperidol at high doses Patients should be treated with the lowest dose of thioridazine needed to treat their symptoms
No takes yet. Share an insight, caveat, or question.
Sean Hennessy (2002) conducted a cohort in Schizophrenia treated with antipsychotic drugs (n=124,718). Thioridazine (and other oral antipsychotics: clozapine, haloperidol, risperidone) vs. Haloperidol (and non-schizophrenic control patients with glaucoma or psoriasis) was evaluated on Diagnosis of cardiac arrest or ventricular arrhythmia (RR 0.9, 95% CI 0.7-1.2). Thioridazine was not associated with an overall increased risk of cardiac arrest or ventricular arrhythmia compared with haloperidol, except at doses >=/day.
Synapse has enriched 10 related papers. Consider them for comparative context: